Dapagliflozin for heart failure according to body mass index: the DELIVER trial.
Carly AdamsonToru KondoPardeep S JhundRudolf A de BoerJose Walter Cabrera HonorioBrian ClaggettAkshay S DesaiMarco Antonio Alcocer GambaWaleed Al HabeebAdrian F HernandezSilvio E InzucchiMikhail N KosiborodCarolyn S P LamAnna Maria LangkildeDaniel LindholmErasmus BachusSheldon E LitwinFelipe MartinezMagnus PeterssonSanjiv J ShahMuthiah VaduganathanPham Nguyen VinhUlrica WilderängScott D SolomonJohn Joseph Valentine McMurrayPublished in: European heart journal (2022)
Obesity is common in patients with HFpEF and is associated with higher rates of heart failure hospitalization and worse health status. Treatment with dapagliflozin improves cardiovascular outcomes across the spectrum of BMI, leads to greater symptom improvement in patients with obesity, compared with those without, and has the additional benefit of causing modest weight loss.
Keyphrases
- weight loss
- heart failure
- body mass index
- weight gain
- bariatric surgery
- insulin resistance
- roux en y gastric bypass
- metabolic syndrome
- gastric bypass
- high fat diet induced
- type diabetes
- left ventricular
- cardiac resynchronization therapy
- study protocol
- acute heart failure
- atrial fibrillation
- physical activity
- glycemic control
- clinical trial
- phase ii
- combination therapy
- phase iii